These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21556623)

  • 21. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
    Jayson GC; Middleton M; Lee SM; Ashcroft L; Thatcher N
    Br J Cancer; 1998 Aug; 78(3):366-9. PubMed ID: 9703284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
    Schlag P; Manasterski M; Gerneth T; Hohenberger P; Dueck M; Herfarth C; Liebrich W; Schirrmacher V
    Cancer Immunol Immunother; 1992; 35(5):325-30. PubMed ID: 1394336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma.
    Guida M; Latorre A; Selvaggi F; Ditonno P; Lorusso V; Mastria A; Delena M
    Int J Oncol; 1997 Mar; 10(3):487-91. PubMed ID: 21533401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
    Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
    Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
    Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
    Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
    Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
    Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
    Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
    Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
    J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
    Clark JI; Gaynor ER; Martone B; Budds SC; Manjunath R; Flanigan RC; Waters WB; Sosman JA
    Clin Cancer Res; 1999 Sep; 5(9):2374-80. PubMed ID: 10499607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
    Lissoni P; Barni S; Tancini G; Andres M; Scardino E; Cardellini P; Frascaroli M; Ardizzoia A; Crispino S; Vicini D
    Arch Ital Urol Androl; 1993 Apr; 65(2):123-8. PubMed ID: 8330055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
    Elias L; Lew D; Figlin RA; Flanigan RC; Thompson ME; Triozzi PL; Belt RJ; Wood DP; Rivkin SE; David E
    Cancer; 2000 Aug; 89(3):597-603. PubMed ID: 10931459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.